Abstract
The present study deals with the formulation and evaluation of Artemisinin HCl nanoparticles. Artemisinin is a sesquiterpene lactone chemical extract from Artemisia annua (sweet wormwood), is poorly soluble in water and a fast-acting blood schizonticide effective in treating the acute attack of malaria (including chloroquine – resistant and celebral malaria). Artemisinin are effective against multi-resistant strains of P. falciparum. The purpose of the present work is to minimize the dosing frequency, taste masking and toxicity and to improve the therapeutic efficacy by formulating Artemisinin HCl nanoparticles. Artemisinin HCl nanoparticles were formulated by solvent evaporation method using polymer poly(ε-caprolactone) with five different formulations. Nanoparticles were characterized by determining its particle size, polydispersity index, drug entrapment efficiency, particle morphological character and drug release. The particle size ranged between 100nm to 240nm. Drug entrapment efficacy was > 99%. The in-vitro release of nanoparticles were carried out which exhibited a sustained release of Artemisinin HCl from nanoparticles up to 24hrs. The results showed that nanoparticles can be a promising drug delivery system for sustained release of Artemisinin HCl.
References
N.S. Santos-Magalhães, (2010) V.C.F. Mosqueira / Advanced Drug Delivery Reviews 62 560–562.
G.M. Barratt, (2000) Therapeutic applications of colloidal drug carriers, Pharm. Sci. Technol. Today 3 163–171.
C. Vauthier, P. Couvreur, (2007) Nanomedicines: a new approach for the treatment of serious diseases, J. Biomed. Nanotechnol. 3 223–234.
M.L. Forrest, G.S. Kwon, (2008) Clinical developments in drug delivery nanotechnology, Adv. Drug Deliv. Rev. 60 861–862.
The merck index. “an encyclopedia of chemicals, drug and biological”, Merck research laboratories,13thedition. 2001. pp 139.
Sweetman Sean C. Martindale “The Complete Drug Reference “, 33th Edition .pp 2002.431-432, 438-440, 436-437.
Global malaria control and elimination: report of a meeting on containment of artemisinin tolerance, 19January 2008. Geneva, World Health Organization, 2008.
http://www.who.int/malaria/docs/drugresistance/Malari a_Artemisinin.pdf
Jain NK (2010). Pharmaceutical technology: pharmaceutical nanotechnology. Available at: http://nsdl.niscair.res.in/bitstr
/123456789/748/1/revised+Pharmaceuticall+Nanotec
h. pdf. Accessed on 23 November.
Gupta R B. “Fundamentals of drug nanoparticles”, In: Gupta R B, Kompella U B. ed. Nanoparticles technology for drug delivery. Taylor & Francis Group, New York. (2006) 17.
Mohanraj V J, Chen Y (2006). Nanoparticles-a review. Trop J Pharm Res. 5: 561-573.
Thassu D, Pathak Y, Deleers M. “Nanoparticulate drugdelivery dystems: an overview”, In: Thassu D, Deleers M, Pathak Y. eds. Volume 166. (2007) Informa healthcare USA, Inc.270 Madison avenue New York.
Lindenberg M, Kopp S, Dressman JB (2004). Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265–278.
Florey Klaus. Analytical profiles of drug substances. Volume-14. Academic press. Pp159. [14]
Shafiq-un-Nabi Sheikh, Faiyaz Shakeel, Talegaonkar Sushma, Ali Javed, Baboota Sanjula, Ahuja Alka,. Khar Roop K, and Ali Mushir (2007). Formulation Development and Optimization Using Nanoemulsion Technique:A Technical Note. AAPS PharmSciTech 8 (2) Article 28.
Delphine Moinard-Checot,Chevalier Y,Riancon Stephanie,Benney Laurent, Hastem Fessi (2008) Mechanism of nanocapsules formulation by emulsion- diffusion process. Journal of Colloidal and Interface Science. 317:458-468.
Kreuter J (1994). Nanoparticles in Colloidal Drug Delivery Systems. New York, Marcel Dekker Inc: 9nd. 219-220.
Zeta potential of colloids in water and waste water" (1985). ASTM Standard D 4187-82. American Society for Testing and Materials
Jelvehgari M., Barar J., Valizadeh H., Delf Loveymi B. and Ziapour M, (2010). Preparation of Diclofenac Sodium Composite Microparticles with Improved Initial Release Property.Transaction F: Nanotechnology 17(2):79-89.
Pignatello R, Ricupero N, Bucolo, Maugeri F Maltese A and Puglisi G (2006). preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.AAPS Pharma Sci tech 24:7:E27.
Nidhin M, Indumathy R, Sreeram KJ and Balachandran U (2008). synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bull Mater Sci 31:93-96.
Dash Suvakanta, Murthy Padala Narasimha, Nath Lilakanta And Chowdhury Prasanta (2010). Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems. Acta Poloniae Pharmaceutica-Drug Research, 67(3): 219-220.
K. Satish Kumar D. Gnanaprakash, K. Mayilvaganan, C. Arunraj And S. Mohankumar (2012). Chitosan-Gold Nanoparticles As Delivery Systems For Curcumin. IJPSR 3(11): 4537-4538.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA (1983). Int. J. Pharm. 15:25.
Hixson AW, Crowell JH (1931). Ind. Eng. Chem.23:923.
Allemann E, Gurny R, Doelker E (1993). Drug-loaded nanoparticles- preparation methods and drug targeting tissues. Eur J Pharm Biopharm 39: 173-191.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array